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Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis involves 
persistent serum amylase levels of ≥three times the standard upper limit. However, these 
criteria were mostly based on retrospective studies and not necessarily supported by 
diagnostic imaging. Our prospective study aimed to investigate cut-off serum amylase levels 
suggesting post-ERCP pancreatitis using computed tomography as the gold standard. 
Methods: 
We prospectively followed 2078 cases. Computed tomography was performed in patients 
whose serum amylase levels exceeded the institutional upper limit 12–24 h after ERCP. Two 
expert radiological diagnosticians blindly assessed the images and judged the presence or 
absence of pancreatitis. Correlations between serum amylase levels with pancreatitis were 
investigated using receiver operating characteristic analysis. 
Results: 
Amylase levels increased in 416 (23.2%) of 1789 cases included, and 350 cases were 
analysed using computed tomography. Post-ERCP pancreatitis was diagnosed in 12.0% 
(214/1789). The cut-off amylase levels for judging pancreatitis after 12–24 h was 2.75 times 






The appropriate cut-off serum amylase level for judging post-ERCP pancreatitis at 12–24 h 
after ERCP was 2.75 times higher than the institutional upper limit. These results may 




Severe post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis is 
potentially fatal. It is reported that the incidence was 2.6–9.7% and the mortality rate was 0.3–
0.7%.1,2 Therefore, it is important to diagnose pancreatitis rapidly and accurately in routine 
practice. In general, acute pancreatitis is diagnosed on the basis of the presence of two of the 
following three features: (1) abdominal pain and tenderness, (2) elevated pancreatic enzyme 
blood levels and (3) abnormal diagnostic imaging findings in the pancreas associated with 
acute pancreatitis.3 Abdominal pain and serum amylase (AMY) levels have high sensitivity 
and specificity for the diagnosis of acute pancreatitis.4-6 Recent systematic review reported 
that the sensitivity was 0.72, and the specificity was 0.93.7 Accordingly, it is often easy to 
diagnose acute pancreatitis without detailed image inspection.  
On the other hand, after ERCP, hyperamylasemia can occur because of non-specific 
elevation of salivary amylase. It can be difficult to evaluate abdominal pain because of 
sedation or distinguish it from abdominal pain secondary to endoscopic procedures, such as 
insufflation of the intestinal tract. Therefore, a definitive diagnosis of post-ERCP pancreatitis 





Diagnosis of post-ERCP pancreatitis is defined as serum AMY levels at least three 
times higher than the upper limit of the standard for 24 h after the procedure, requiring 
admission or prolongation of planned admission to more than 2 days, as reported by Cotton et 
al.10 Abdominal pain and hyperamylasemia over three times normal upper limit were important 
findings; however, cases with pancreatitis and no abdominal pain or with serum AMY <three 
times the normal value upper limit after ERCP exist.10-12 In addition, it was unclear as to when 
post-ERCP pancreatitis is highly suspected. 
On the basis of these previous studies, definitive criteria including cut-off AMY 
values for post-ERCP pancreatitis are insufficient. Furthermore, many studies were 
retrospective and included small samples. In this study, we used computed tomography (CT) 
findings as the gold standard indicator of ERCP-induced pancreatitis. We aimed to clarify the 
cut-off serum AMY levels that suggest post-ERCP pancreatitis in a prospective multicenter 
observational study.  
 
Patients and Methods 
Study design 
A multicenter, prospective observational study was performed in patients who underwent 
ERCP. In total, five high-volume centres in Japan were included in this study. The recruitment 







We prospectively enrolled 2078 patients who underwent ERCP examinations. We excluded 
patients on the basis of predetermined conditions (unreachable papilla of Vater, biliary tract 
reconstruction, pancreatitis observed before the examination, patients with increased serum 
AMY levels before the examination, ascites retention or massive tumour invasion that 
rendered investigation of pancreatitis by images difficult) (Figure 1). The protocol of this 
study was registered in the UMIN clinical trial registration system (UMIN000024814). The 
study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as 
reflected in a priori approval by the institution's human research committee and received 
approval from the ethics committee of Shiga University of Medical Sciences (# 26-191 on 3th, 
February 2015) and conformed to its guidelines. Each patient provided written informed 
consent to participate in all study-related procedures. The examination items were patients' 
backgrounds, procedures, the presence or absence of abdominal pain within 4 h of 
examination or that persisted for 12 to 24 h （the day after the examination） and serum AMY 
levels at 2 h after the examination and at 12 to 24 h. As for the volume of infusion during the 
examination and the type of medication administered, we followed each facility's policy. CT 
studies were promptly performed on patients whose serum AMY levels exceeded the 
institutional upper limit at 12 to 24 h after ERCP to investigate the presence or absence of 
pancreatitis-related findings. The decision to use contrast medium for CT was at the discretion 
of the attending doctors.  
 





Two expert radiological diagnosticians (SO and AI) who were blinded to clinical information 
independently assessed the CT images and judged the presence or absence of pancreatitis on 
the basis of the Balthazar score and CT severity index (CTSI).13-18 All patients who 
participated in this study had CT scans within one month before ERCP. They compared CT 
image from before and after ERCP to precisely diagnose the pancreatitis. In the case that the 
diagnosis in the primary interpretation was different, they reassessed both images and reached 
a conclusion by consensus to minimize the influence of inter-reader variability. 
 
Statistical analysis 
All statistical analyses were performed using Prism version 6.05 (GraphPad, San Diego, Calif). 
P < 0.05 was considered statistically significant. Receiver operating characteristic analyses 
was performed to calculate the cut-off values of the serum AMY levels by identifying the 
point closest to the 1.0 angle. Abdominal pain under 4 h and pain that persisted longer than 
12 h, with the presence or absence of pancreatitis, were investigated using the chi-square test. 
 
Results 
Among the 2078 ERCP cases enrolled, 1789 cases were analysed after exclusion. Of the 416 
patients （23.2%） with high level of serum AMY on the following day, 350 underwent CT 
imaging (Figure 1). Of the 350 cases analysed by CT, there were no significant differences 
in age, sex, American Society of Anesthesiologists physical status and treatment contents for 





pancreatic cancer was significantly higher in the pancreatitis group, and the prevalence of 
choledocholithiasis was lower in the non-pancreatitis group (Table 1). Contrast-enhanced CT 
was performed in 13 of 250 (3.7%) who underwent CT interpretation. One of them had 
necrotizing pancreatitis with less than 30% necrotic area. 
The cut-off AMY level for judging the presence or absence of pancreatitis on the 
following day was 2.75 times higher than the institutional upper limit (sensitivity: 70.1%, 
specificity: 75.7%, positive likelihood ratio: 2.88, negative likelihood ratio: 0.39) with an 
area under the curve (AUC) of 0.77. The cut-off level after 2 h was 2.73 times higher than 
the institutional upper limit (sensitivity: 45.1%, specificity: 79.7%, positive likelihood ratio: 
2.19, negative likelihood ratio: 0.69) with an AUC of 0.63 (Figure 2, Table 2).  
Abdominal pain under 4 h was noted in 40 of the 214 patients in the pancreatitis 
group (18.7%) and 12 of 136 patients in the non-pancreatitis group (8.8%) with a sensitivity 
of 18.7%; specificity, 91.2%; positive likelihood ratio, 2.11; and negative likelihood ratio, 
0.89. Abdominal pain that persisted longer than 12 h occurred in 81 patients in the 
pancreatitis group and 12 in the non-pancreatitis group with a sensitivity of 37.9%, 
specificity of 91.2%, positive likelihood ratio of 3.97 and negative likelihood ratio of 0.71 
(Table 3).  
When we set the cut-off value of the serum AMY value on the next day judged as 
pancreatitis to 2.75 times at 1 day after ERCP, the sensitivity and specificity of pancreatitis in 
combination with AMY >2.75 and abdominal pain and AMY >2.75 or abdominal pain were 







In this study, we analysed the correlation between serum AMY levels after ERCP and CT 
images using professional interpretation in a multicenter prospective study. We established a 
cut-off serum AMY level for the diagnosis of post-ERCP pancreatitis. With respect to 
abdominal pain, it was clear that the sensitivity was not sufficient although the specificity was 
high.  
The cutoff value of serum amylase defining post-ERCP pancreatitis have remained 
controversial for many years. Artifon et alet reported that, based on ERCP, 41.9% of 
pancreatitis cases were overlooked and 30% of pancreatitis cases had AMY values that were 
less than three times the normal upper limit, as per Cotton’s definition alone, when lipase and 
CT findings were taken into consideration.11 Wang et al reported that asymptomatic 
hyperamylasemia (over three times the normal upper limit) was observed in 14.7% after 
ERCP.19 In addition, Uchino et al reported that post-ERCP pancreatitis was confirmed by 
detailed CT examination in 37% of patients with hyperamylasemia without abdominal pain at 
18 h after ERCP.12 
In this study, we set the cut-off value by performing CT for all cases where serum 
AMY exceeded the upper limit of the facility reference value, picking up as many cases of 
minimal pancreatitis as possible. The appropriate cut-off serum AMY level for judging ERCP-
induced pancreatitis at 12–24 h after ERCP was 2.75 times higher than the institutional upper 





on the day following ERCP.  
When the cut-off value is set to 2.75 times, it becomes possible to diagnose about 
70% of post-ERCP pancreatitis by serum AMY alone. The severity of all pancreatitis cases 
overlooked by this cut-off value setting (30%) was mild; therefore, this threshold appears 
acceptable as a new clinical diagnostic criterion.  
According to the previous reports, the frequency of post-ERCP pancreatitis is 2.6%–
9.7%.1,2,20-22 The frequency of post-ERCP pancreatitis in this study was 12.0%, which is 
slightly high; however, this is considered to be the result of picking up many more cases of 
mild pancreatitis using professional interpretation and correction prospectively. 
The role of abdominal pain for the diagnosis of post-ERCP pancreatitis has also been 
ambiguous for many years. Our data showed that although its specificity is high, its sensitivity 
is low, especially for abdominal pain within 4 h. Patients may not complain of abdominal pain 
because of the prolonged effects of sedatives after examination or the fact that very mild 
pancreatitis may not be picked up in detail. Indeed, in non-ERCP-related pancreatitis, some 
patients do not complain of abdominal pain.23 Therefore, from the results of this study, if post-
ERCP pancreatitis was diagnosed with weight on abdominal pain, many cases would be 
overlooked. Therefore, we should start treatment for the pancreatitis in some patients, even 
without abdominal pain. To increase the diagnostic accuracy of post-ERCP pancreatitis, a 
combination of elevated serum AMY value after 12–24 h and abdominal pain sustained for 
12–24 h after examination was useful (Table 3). 





The infusion volume at each facility was approximately 1500–2000 mL on the day of ERCP, 
and the volume after the following day depended on the physician’s decision. This suggested 
that the cut-off value of serum amylase defining post-ERCP pancreatitis is universal and is 
not affected by infusion volume. 
This study had several limitations. Firstly, CT was not taken, for various reasons, in 
63 (15.1%) of the 416 cases where pancreatic enzyme elevations were observed 12 to 24 h 
after ERCP. However, in 70% of cases, levels remained at the upper limit of the facility 
reference value of two times or less, and no cases reported abdominal pain. Therefore, the 
influence on detecting cases of pancreatitis was considered to be minimal. Secondly, the 
purpose of this study was to set a cut-off serum AMY value to indicate post-ERCP pancreatitis, 
not early detection or identification of predictive factors. The serum AMY value after 2 h had 
low sensitivity and specificity for pancreatitis diagnosis and is an unsuitable early predictive 
marker as reported in the previous reports.11,24 One of the reasons is that elevated serum AMY 
immediately after endoscopic examination is likely to be derived from salivary glands.25 
Therefore, other pancreas-specific markers (pancreas-specific AMY, lipase, etc.) will be 
necessary as a predictive marker for early prediction of post-ERCP pancreatitis. We did not 
select pancreas-specific AMY or lipase for this study point because these were not measured 
at all facilities at nights or on holidays and, therefore, not considered suitable for identification 







Serum AMY levels on the day following ERCP were highly correlated with CT-defined post-
ERCP pancreatitis. The appropriate cut-off serum AMY level for judging ERCP-related 
pancreatitis is 2.75 times higher than the institutional upper limit. This newly set cut-off 
value of serum AMY can help diagnose ERCP-induced pancreatitis, independent of CT 
imaging. These results may clarify the definition of post-ERCP pancreatitis. 
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Figure 1. Flow diagram. There were 2078 patients who received ERCP. We excluded 289 
cases (not reached the papilla in nine cases, post-biliary reconstruction in 63 cases, developed 
pancreatitis before ERCP in 74 cases, elevated amylase before ERCP in 120 cases and ascites 
or fluid collection due to biliary pancreatic cancer in 23 cases). Serum amylase level elevated 
in 416 of 1789 cases enrolled. Sixty-six cases were excluded (CT is not performed CT at the 
discretion of the physician in 63 cases, the patients refused CT examination in two cases and 
bile duct perforation in one case). We analysed 350 cases using CT diagnosis of two expert 
radiologists. 
 
Figure 2. Receiver operating characteristic curves of serum amylase level at 2 h (A) and 12–
24 h (B) after ERCP for diagnosing post-ERCP pancreatitis.  












TABLE 1. The Clinical Characteristics of the Patients Received CT Analysis 
  
Pancreatitis 
(n = 214) 
No Pancreatitis 
(n = 136) 
P 
Male/female, n 101/113 66/70 0.81 
Age, median (range), y 72.8 (33–106) 73.1 (41–96) 0.78 
ASA, mean (SD) 1.56 (0.67) 1.68 (0.69) 0.10 
Disease, n (%)       
     CBD stone 77 (36.0) 72 (52.9)   
     Neoplasm 80 (37.4) 27 (19.9)   
     Others 57 (26.6) 37 (27.2)   
Procedure, n (%)    
   Diagnostic 44 (20.6) 18 (13.2)  
   Therapeutic 170 (79.4) 118 (86.8)  
CT grade *, n (%)    
   A 0 136 (100)  
B 33 (15.4) 0 (0)  
C 123 (57.5) 0 (0)  
D 28 (13.1) 0 (0)  
E 30 (14.0) 0 (0)  
 
*CT grade according to CT severity index  
Grade A; Normal pancreas  
Grade B; Focal or diffuse enlargement of the pancreas 
Grade C; Intrinsic pancreatic abnormalities associated with haziness and streaky densities 
representing inflammatory changes in the peripancreatic fat 





Grade E; Two or more poorly defined fluid collections or presence of gas adjacent to the 
pancreas 




AUC Sensitivity, % Specificity, % PLR NLR Cut-off value 
(times the upper 
limit of normal) 
2 h 0.63 45.2 79.3 2.19 0.69 2.73 
12–24 h 0.77 70.1 75.7 2.88 0.39 2.75 
 




TABLE 3. Sensitivity and Specificity of Abdominal Pain and Serum Amylase Level at 2 
and 12–24 h After the Examination for Post-ERCP Pancreatitis  
Sensitivity, % Specificity, % PLR NLR 
Abdominal pain at 2 h 19.2 91.2 2.11 0.89 
Abdominal pain at 12–24 h 38.1 91.2 4.29 0.68 
AMY > 2.75 and Abdominal pain 
at 12–24 h 
34.0 97.3 9.82 0.68 
AMY > 2.75 or Abdominal pain 
at 12–24 h 
81.4 63.1 1.89 0.67 
 
PLR: Positive likelihood ratio; NLR: Negative likelihood ratio 
 
 
